Myriad Genetics (MYGN) Cash & Current Investments (2016 - 2025)
Historic Cash & Current Investments for Myriad Genetics (MYGN) over the last 17 years, with Q3 2025 value amounting to $145.4 million.
- Myriad Genetics' Cash & Current Investments rose 4554.55% to $145.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $145.4 million, marking a year-over-year increase of 4554.55%. This contributed to the annual value of $102.4 million for FY2024, which is 2732.43% down from last year.
- As of Q3 2025, Myriad Genetics' Cash & Current Investments stood at $145.4 million, which was up 4554.55% from $74.4 million recorded in Q2 2025.
- In the past 5 years, Myriad Genetics' Cash & Current Investments registered a high of $366.1 million during Q3 2021, and its lowest value of $74.4 million during Q2 2025.
- Its 5-year average for Cash & Current Investments is $156.1 million, with a median of $121.6 million in 2023.
- As far as peak fluctuations go, Myriad Genetics' Cash & Current Investments skyrocketed by 12824.19% in 2021, and later plummeted by 7056.84% in 2023.
- Myriad Genetics' Cash & Current Investments (Quarter) stood at $338.8 million in 2021, then crashed by 66.09% to $114.9 million in 2022, then rose by 22.63% to $140.9 million in 2023, then dropped by 27.32% to $102.4 million in 2024, then soared by 41.99% to $145.4 million in 2025.
- Its last three reported values are $145.4 million in Q3 2025, $74.4 million for Q2 2025, and $91.8 million during Q1 2025.